Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Kidney360. 2023 Oct 1;4(10):1454-1466. doi: 10.34067/KID.0000000000000171. Epub 2023 Jun 2.
Kelch-like erythroid cell-derived protein with CNC homology (ECH)-associated protein 1-NF (erythroid-derived 2)–like 2 pathway increases GFR without an appreciable increase in intraglomerular pressure. Kelch-like ECH-associated protein 1-NF (erythroid-derived 2)–like 2 pathway regulates GFR through changes in filtration area by modulating calcium dynamics and contractility in glomerular cells.
Literature data suggest that the activation of the Kelch-like ECH-associated protein 1 (Keap1)-NF (erythroid-derived 2)–like 2 (Nrf2) pathway increases GFR in patients with type 2 diabetes and CKD. However, the mechanisms whereby the Keap1-Nrf2 pathway regulates GFR are unknown.
Various renal physiological parameters were assessed in C57BL/6 mice (wild-type), -deficient mice, and -activated knockdown mice. In addition, these parameters were assessed after the administration of receptor targeting agent (RTA) dh404 (CDDO‐dhTFEA), an Nrf2 activator.
Pharmacologic and genetic - activation increased renal blood flow ( < 0.05), glomerular volume ( < 0.05), and GFR ( < 0.05) but did not alter the afferent-to-efferent arteriolar diameter ratio or glomerular permeability. Calcium influx into the podocytes through transient receptor potential canonical (TRPC) channels in response to HO was suppressed by Keap1-Nrf2 activation and TRPCs inhibition. Treatment with a TRPC6 and TRPC5 inhibitors increased single-nephron GFR in wild-type mice.
In conclusion, the Keap1-Nrf2 pathway regulates GFR through changes in ultrafiltration by modulating redox-sensitive intracellular calcium signaling and cellular contractility, mediated through TRPC activity, in glomerular cells, particularly the podocytes.
Kelch 样红细胞衍生蛋白与 CNC 同源(ECH)相关蛋白 1-NF(红细胞衍生 2)样 2 通路增加 GFR,而不会使肾小球内压显著升高。Kelch 样 ECH 相关蛋白 1-NF(红细胞衍生 2)样 2 通路通过调节肾小球细胞中的钙动态和收缩性来改变滤过面积,从而调节 GFR。
文献数据表明,激活 Kelch 样 ECH 相关蛋白 1(Keap1)-NF(红细胞衍生 2)样 2(Nrf2)通路可增加 2 型糖尿病和 CKD 患者的 GFR。然而,Keap1-Nrf2 通路调节 GFR 的机制尚不清楚。
在 C57BL/6 小鼠(野生型)、-缺陷型小鼠和 -激活敲低型小鼠中评估了各种肾脏生理参数。此外,还评估了受体靶向剂(RTA)dh404(CDDO-dhTFEA)给药后这些参数。
药理学和遗传学 - 激活增加了肾血流量(<0.05)、肾小球体积(<0.05)和 GFR(<0.05),但不改变入球小动脉和出球小动脉直径比或肾小球通透性。Keap1-Nrf2 激活和 TRPC 抑制抑制了对 HO 反应的足细胞中通过瞬时受体电位经典型(TRPC)通道的钙内流。在野生型小鼠中,TRPC6 和 TRPC5 抑制剂的治疗增加了单肾单位 GFR。
总之,Keap1-Nrf2 通路通过调节氧化还原敏感的细胞内钙信号和细胞收缩性来调节 GFR,通过调节肾小球细胞中 TRPC 活性来改变超滤,特别是足细胞。